Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures (2016 - 2026)

Amphastar Pharmaceuticals has reported Gains from Sales and Divestitures over the past 13 years, most recently at $372602.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 4.17% year-over-year to $372602.0; the TTM value through Dec 2025 reached $372602.0, down 4.17%, while the annual FY2025 figure was $372602.0, 4.17% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $372602.0 at Amphastar Pharmaceuticals, roughly flat from $372218.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $493718.0 in Q4 2021 and troughed at $338280.0 in Q1 2025.
  • A 5-year average of $419789.0 and a median of $416990.0 in 2021 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: decreased 21.39% in 2021 and later increased 0.01% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $493718.0 in 2021, then fell by 3.17% to $478068.0 in 2022, then decreased by 7.86% to $440484.0 in 2023, then fell by 11.73% to $388816.0 in 2024, then decreased by 4.17% to $372602.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for AMPH at $372602.0 in Q4 2025, $372218.0 in Q3 2025, and $367827.0 in Q2 2025.